Clinical effect of aspirin combined with low-molecular-weight heparin in the prevention of preeclampsia in patients with hypertension during pregnancy / 中国基层医药

ABSTRACT

Objective:To observe the clinical effects of aspirin combined with low-molecular-weight heparin in the prevention of preeclampsia in patients with hypertension during pregnancy.Methods:From October 2017 to December 2018, 120 patients with hypertension during pregnancy who were treated in the Maternal and Child Health Hospital of Cixi were selected.The patients were divided into control group and observation group according to the wishes of pregnant women and informed consent, with 60 patients in each group.Control group received single oral aspirin 100 mg daily from 11-13 + 6 weeks of pregnancy to 36 weeks of pregnancy or 5-10 days before termination of pregnancy.The observation group received 3075 IU of low-molecular-weight heparin subcutaneous injections daily from 11-13 + 6 weeks of pregnancy for 2 weeks, and was orally given aspirin 100 mg daily for 36 weeks or until 5-10 days before termination of pregnancy.The incidence of preeclampoia, adverse pvegnany outcome and complication of the two groups were observed and compared. Results:The incidences of preeclampsia, preterm birth, cesarean section, fetal distress, placental abruption and neonatal asphyxia in the observation group were 15.00%, 20.00%, 36.67%, 11.67%, 6.67% and 1.67%, respectively, which were significantly lower than those in the control group (31.57%, 35.00%, 55.00%, 30.00%, 23.33% and 15.00%, χ 2=4.658, 4.104, 4.061, 6.113, 6.535, 6.981, all P<0.05). The gestational age at delivery[(37.88±3.72)weeks] and the weight of the newborn [(2.63±0.24)kg] in the observation group were significantly larger than those in the control group[(36.11±3.59)weeks, (2.13±0.20)kg]( t=2.652, 12.397, all P<0.05). The incidences of postpartum blood loss, thrombocytopenia, oligohydramnios and pleural and ascites in the observation group were 5.00%, 1.67%, 5.00% and 16.67%, respectively, which were significantly lower than those in the control group (25.00%, 16.67%, 23.33% and 15.00%, χ 2=9.411, 8.106, 8.292, 6.981, all P<0.05). Conclusion:Low-dose aspirin and low-molecular-weight heparin for patients with hypertension during pregnancy can reduce the incidence of preeclampsia and improve adverse pregnancy outcomes, which is worthy of promotion and application.